Outcomes of patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The <scp>MD</scp> Anderson Cancer Center experience

Nivolumab plus ipilimumab (nivo/ipi) is an approved therapy for patients with intermediate-risk or poor-risk metastatic renal cell carcinoma (mRCC). Clinical factors that guide the selection of this regimen mRCC are urgently needed. We retrospectively analyzed medical records who were hospitalized at MD Anderson Cancer Center because cancer-related symptoms and received their first cycle nivo/ipi in inpatient setting. parameters, including demographics, histology, clinical history, response, survival, collected. The 4-month survival probability, progression-free (PFS), overall (OS) calculated using Kaplan-Meier methods. Between November 2017 21 June 2020 identified fit search: 19 (91%) had disease based on International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score; 17 (81%) ≥4 factors; 9 (43%) sarcomatoid features histology. Shortness breath (28%) abdominal pain (19%) two most common reasons hospitalization. Partial response was achieved 14% (3/21) patients. Median PFS all 1.7 months (95% CI 0-3.9); median OS 0-4.2); probability 36% 25%-47%). In retrospective study, a large tertiary referral center derive limited benefit from when started Alternative, more effective systemic therapies should be considered these